However, recombinant IFN-β and newly designed IFN-β derivatives, including fusion molecules with anti-albumin fragment antigen-binding region (Fab) fragments or Galectin-9, have been implemented to treat relapsing-remitting multiple sclerosis (Clerico et al., 2007; Tovey and Lallemand, 2010; Ji et al., 2019; Hamana et al., 2018) (Fig. 1, Table 1). The gene discussed is IFNB1; the disease is relapsing-remitting multiple sclerosis.